Table 1 Description of the studies included in the systematic review.
From: The chemobrain in breast cancer patients: a systematic review and meta-analysis
Author, year | Country | Study design | Age (years) | Chemotherapy | Concurrent therapy | Memory testing prior to chemotherapy | |
|---|---|---|---|---|---|---|---|
Regimen | Time since completion | ||||||
Fan, 200513 | Canada | Prospective cohort | 48 ± NA | CTX/EPI/FU (6 cycles) or doxo/CTX (4 cycles) | 1 year | Radiotherapy Hormone therapy | Yes |
Hurria, 200614 | USA | Prospective cohort | 70 (65–84) # | CTX/MTX/FU (8 cycles) or doxo/CTX (4 cycles) or doxo/CTX/PC (4 cycles) | 6 months | Hormone therapy | Yes |
Tager, 200915 | USA | Prospective cohort | 60 ± 6 | doxo/CTX/PC or doxo/CTX or cytoxan/MTX/5-FU | 6 months | Hormone therapy Radiotherapy | Yes |
Jansen, 201116 | USA | Prospective cohort | 50 ± 9 | doxo/CTX ± Taxane | 6 months | Hormone therapy | Yes |
Chae, 20189 | Singapore | Prospective cohort | 52 ± 9 | Taxane or AC-CT | 6 weeks after start of chemotherapy | None | Yes |
Schrauwen, 202017 | Belgium | Prospective cohort | 47 ± 10 | 5-FU/EPI/CTX/DTX | End of chemotherapy | Radiotherapy Hormone therapy | Yes |
Syed Alwi, 202118 | Malaysia | Cross-sectional | 52 ± 8 | AC-CT-based or AC-CT/Taxane | < 2 years | Radiotherapy Hormone therapy | No |
Juan, 202210 | China | Prospective cohort | 45 ± 9 | EPI/CTX or EPI/CTX/DTX or DTX/CTX | 3 weeks | None | Yes |
Liu, 202419 | China | Cross-sectional | 51 ± 10 | AC-CT or AC-CT/Taxane or CTX | NA | Surgery | No |
Ma, 202420 | China | Prospective cohort | 47 ± 8 | EPI/CTX/DTX or DTX: CTX | 1 week | NA | Yes |
Wu, 202421 | China | Cross-sectional | NA | NA | NA | Surgery and/or radiotherapy | No |
